melatonin has been researched along with Carcinoma, Non-Small Cell Lung in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone." | 9.07 | A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994) |
| "Melatonin is a hormone synthesized in the pineal gland and has widespread physiological and pharmacological functions." | 5.72 | Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. ( Duan, H; Duan, W; Li, X; Lu, G; Shao, C; Wang, J; Wang, Y; Wang, Z; Xie, M; Yan, X; Yu, W, 2022) |
| " In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone." | 5.07 | A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994) |
| " In this study, we evaluated the effect of melatonin on the genotoxic activity of irinotecan in healthy human lymphocytes and a lung cancer cell line (A549) and a colorectal adenocarcinoma cell line (HT29) in vitro." | 3.79 | The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells. ( Kontek, R; Nowicka, H, 2013) |
| "Melatonin is a serotonin-derived pineal gland hormone with many biological functions like regulating the sleep-wake cycle, circadian rhythm, menstrual cycle, aging, immunity, and antioxidants." | 3.01 | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. ( Almalki, WH; Chellappan, DK; Dua, K; Fuloria, NK; Fuloria, S; Gupta, G; Haniffa, SM; Jha, NK; Negi, P; Priya, S; Rohilla, S; Sekar, M; Singh, M; Singh, SK; Subramaniyan, V, 2023) |
| "Melatonin was given orally at 20 mg/day in the evening for at least 2 months." | 2.70 | Anti-angiogenic activity of melatonin in advanced cancer patients. ( Bucovec, R; Conti, A; Lissoni, P; Maestroni, GJ; Malugani, F; Rovelli, F, 2001) |
| "Melatonin is a hormone synthesized in the pineal gland and has widespread physiological and pharmacological functions." | 1.72 | Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. ( Duan, H; Duan, W; Li, X; Lu, G; Shao, C; Wang, J; Wang, Y; Wang, Z; Xie, M; Yan, X; Yu, W, 2022) |
| "Melatonin was proven to possess anticancer actions, whereas its effect on NSCLC and underlying mechanisms remains poorly understood." | 1.51 | Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment. ( Di, S; Guo, K; Han, J; Li, W; Li, X; Liu, D; Ma, Z; Xu, L; Yan, X; Zhang, J; Zhang, Z; Zhu, Y, 2019) |
| "Treatment with melatonin prior to irradiation did not produce any significant change in apoptosis." | 1.40 | CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells. ( Jeong, JW; Kim, JE; Kim, W, 2014) |
| "Treatment with melatonin dose-dependently decreased the viability of H1975 cells harbouring the T790M somatic mutation compared to HCC827 cells with an EGFR active mutation." | 1.40 | Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. ( Kim, EO; Kim, J; Kim, JH; Kim, SH; Lee, D; Lee, H; Lee, J; Yun, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Tang, P | 1 |
| Wang, J | 2 |
| Ye, W | 1 |
| Ge, X | 1 |
| Rong, Y | 1 |
| Ji, C | 1 |
| Wang, Z | 2 |
| Bai, J | 1 |
| Fan, J | 1 |
| Yin, G | 1 |
| Cai, W | 1 |
| Wang, Y | 1 |
| Shao, C | 1 |
| Lu, G | 1 |
| Xie, M | 1 |
| Duan, H | 1 |
| Li, X | 3 |
| Yu, W | 1 |
| Duan, W | 1 |
| Yan, X | 3 |
| Rohilla, S | 1 |
| Singh, M | 1 |
| Priya, S | 1 |
| Almalki, WH | 1 |
| Haniffa, SM | 1 |
| Subramaniyan, V | 1 |
| Fuloria, S | 1 |
| Fuloria, NK | 1 |
| Sekar, M | 1 |
| Singh, SK | 1 |
| Jha, NK | 1 |
| Chellappan, DK | 1 |
| Negi, P | 1 |
| Dua, K | 1 |
| Gupta, G | 1 |
| Ma, Z | 2 |
| Liu, D | 2 |
| Di, S | 2 |
| Zhang, Z | 1 |
| Li, W | 1 |
| Zhang, J | 1 |
| Xu, L | 1 |
| Guo, K | 1 |
| Zhu, Y | 1 |
| Han, J | 2 |
| Kim, W | 1 |
| Jeong, JW | 1 |
| Kim, JE | 1 |
| Yun, M | 1 |
| Kim, EO | 1 |
| Lee, D | 1 |
| Kim, JH | 1 |
| Kim, J | 1 |
| Lee, H | 1 |
| Lee, J | 1 |
| Kim, SH | 1 |
| Sookprasert, A | 1 |
| Johns, NP | 1 |
| Phunmanee, A | 1 |
| Pongthai, P | 1 |
| Cheawchanwattana, A | 1 |
| Johns, J | 1 |
| Konsil, J | 1 |
| Plaimee, P | 1 |
| Porasuphatana, S | 1 |
| Jitpimolmard, S | 1 |
| Yang, Y | 1 |
| Fan, C | 1 |
| Wang, D | 1 |
| Hu, W | 1 |
| Reiter, RJ | 1 |
| Hu, S | 1 |
| Shen, G | 2 |
| Yin, S | 2 |
| Xu, W | 1 |
| Hu, B | 2 |
| Mazzoccoli, G | 4 |
| Sothern, RB | 3 |
| Pazienza, V | 2 |
| Piepoli, A | 2 |
| Muscarella, LA | 3 |
| Giuliani, F | 3 |
| Tarquini, R | 2 |
| Parrella, P | 1 |
| Fazio, VM | 1 |
| Polyakova, V | 1 |
| Kvetnoy, IM | 1 |
| Durfort, T | 1 |
| Francois, JC | 1 |
| Kontek, R | 1 |
| Nowicka, H | 1 |
| Lissoni, P | 6 |
| Chilelli, M | 1 |
| Villa, S | 1 |
| Cerizza, L | 1 |
| Tancini, G | 5 |
| Norsa, A | 1 |
| Martino, V | 1 |
| Hu, SL | 1 |
| Wang, WD | 1 |
| Xu, WP | 1 |
| Wang, H | 1 |
| Zhang, Q | 1 |
| Meregalli, S | 1 |
| Fossati, V | 1 |
| Paolorossi, F | 2 |
| Barni, S | 4 |
| Frigerio, F | 1 |
| Ardizzoia, A | 3 |
| Ricci, G | 1 |
| Aldeghi, R | 1 |
| Brivio, F | 1 |
| Tisi, E | 3 |
| Rovelli, F | 3 |
| Rescaldani, R | 2 |
| Ghielmini, M | 1 |
| Pagani, O | 1 |
| de Jong, J | 1 |
| Pampallona, S | 1 |
| Conti, A | 2 |
| Maestroni, G | 1 |
| Sessa, C | 1 |
| Cavalli, F | 1 |
| Malugani, F | 1 |
| Bucovec, R | 1 |
| Maestroni, GJ | 1 |
| Ballabio, D | 1 |
| Benenti, C | 1 |
| Angeli, M | 1 |
| Crispino, S | 1 |
| Archili, C | 1 |
| De Toma, D | 1 |
| Pipino, G | 1 |
2 reviews available for melatonin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kidney Neoplasms; Lung Neoplasms; | 2023 |
Melatonin as a potential anticarcinogen for non-small-cell lung cancer.
Topics: Anticarcinogenic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Humans; Lung | 2016 |
10 trials available for melatonin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; | 2003 |
Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status.
Topics: Adult; Aged; Bromocriptine; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Female; Humans; Male; | 2006 |
[The effect of amino acid nutritional support on serum tryptophan and melatonin in lung cancer patients receiving chemotherapy].
Topics: Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; C | 2006 |
A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorec | 1994 |
Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carc | 1999 |
Anti-angiogenic activity of melatonin in advanced cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; C | 2001 |
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Topics: Biopterins; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; | 1992 |
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance; Humans; Lung Neoplasms; Mel | 1992 |
11 other studies available for melatonin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Extracellular vesicles derived from melatonin-preconditioned mesenchymal stem cells containing USP29 repair traumatic spinal cord injury by stabilizing NRF2.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Extracellular Vesicles; Lung Neoplasms; Melatonin; Mesenchy | 2021 |
Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Diseas | 2022 |
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Down-Regulation; Gene Expression Reg | 2019 |
CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antioxidants; Apoptosis; Blotting, Western; Ca | 2014 |
Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; ErbB Receptors; Flow Cytometry; Gef | 2014 |
Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Circadian Rhythm; | 2009 |
Circadian aspects of growth hormone-insulin-like growth factor axis function in patients with lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous | 2012 |
Alteration of hypothalamic-pituitary-thyroid axis function in non-small-cell lung cancer patients.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Circadian Rhythm; Female; Humans; Hypot | 2012 |
Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls.
Topics: Adult; Analysis of Variance; B-Lymphocyte Subsets; Body Mass Index; Carcinoma, Non-Small-Cell Lung; | 2012 |
Chronodisruption in lung cancer and possible therapeutic approaches.
Topics: Adenocarcinoma; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chronobiology Disor | 2011 |
The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.
Topics: Adenocarcinoma; Adult; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcin | 2013 |